Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

Ho Chi Minh City is currently facing a critical shortage of radiopharmaceuticals needed for PET/CT scans, crucial in ...

Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer ...

Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate ...

Pharmaceutical heavyweights like Bristol Myers Squibb, AstraZeneca, and Eli Lilly are betting big on radiopharmaceuticals, ...

Just two years into its existence, radioisotope producer PanTera has drawn 93 million euros ($102.5 million) in an ...

如果您想了解有关原子能机构工作的更多信息，请注册获取我们的每月动态，其中包含我们最重要的新闻、多媒体和其他信息。 电子信箱地址 * 出版物高级搜索 国际原子能机构科学和技术出版物可以通过多种参数进行检索：出版年份、主题和类型。使用搜索框 ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...

Unearthing novel targets for radiopharmaceuticals from ACP3m, AVB6, AVB8, and PDL-1 with Philochem, TRIMT, Fusion-AstraZeneca ...

如果您想了解有关原子能机构工作的更多信息，请注册获取我们的每月动态，其中包含我们最重要的新闻、多媒体和其他信息。